Genetics and beyond : Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center
Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody-drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 25(2024), 4 vom: 16. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kraus, Fabian B T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 27.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms25042345 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36887009X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36887009X | ||
| 003 | DE-627 | ||
| 005 | 20240229164614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms25042345 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM36887009X | ||
| 035 | |a (NLM)38397025 | ||
| 035 | |a (PII)2345 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kraus, Fabian B T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetics and beyond |b Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody-drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antibody–drug conjugates | |
| 650 | 4 | |a cervical cancer | |
| 650 | 4 | |a checkpoint inhibitors | |
| 650 | 4 | |a human papillomavirus | |
| 650 | 4 | |a kinase inhibitors | |
| 650 | 4 | |a molecular tumor board | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a targeted therapies | |
| 650 | 4 | |a vaginal cancer | |
| 650 | 4 | |a vulvar cancer | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Sultova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Heinrich, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Westphalen, C Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a Tauber, Christina V |e verfasserin |4 aut | |
| 700 | 1 | |a Kumbrink, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Rudelius, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Klauschen, Frederick |e verfasserin |4 aut | |
| 700 | 1 | |a Greif, Philipp A |e verfasserin |4 aut | |
| 700 | 1 | |a König, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Chelariu-Raicu, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Czogalla, Bastian |e verfasserin |4 aut | |
| 700 | 1 | |a Burges, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Mahner, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Wuerstlein, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Trillsch, Fabian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 25(2024), 4 vom: 16. Feb. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:4 |g day:16 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms25042345 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 4 |b 16 |c 02 | ||